Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers

Marie Stiborová, Eva Frei, Volker M. Arlt, Heinz H. Schmeiser

Jazyk angličtina Země Česko

Typ dokumentu přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc10018501

BACKGROUND: Ingestion of aristolochic acid (AA) is associated with the development of aristolochic acid nephropathy (AAN), which is characterized by chronic renal failure, tubulointerstitial fibrosis and urothelial cancer. AA may also cause another type of kidney fibrosis with malignant transformation of the urothelium, called Balkan Endemic Nephropathy (BEN). The compound predominantly responsible for the nephropathy and urothelial cancer of AA, is aristolochic acid I (AAI) which is a genotoxic mutagen after metabolic activation The activation pathway involves reduction of the nitro group to a cyclic N-acylnitrenium ion that can form covalent DNA adducts. These specific DNA adducts have been detected in experimental animals exposed to AAI, and in urothelial tissues from AAN patients. In rodent tumours induced by AAI, 7-(deoxyadenosin-N(6)-yl)aristolactam I was the most abundant DNA adduct formed and associated with activation of ras oncogenes through a characteristic transversion mutation. Such A:T-->T:A mutations have been identified in TP53 of urothelial tumour DNA of an AAN patient and in several patients suffering from BEN along with specific AA-DNA adducts. Understanding which enzymes are involved in AAI activation to species forming DNA adducts and/or detoxification to its O-demethylated metabolite aristolochic acid Ia (AAIa) is important in order to assess susceptibility to this carcinogen. METHODS AND RESULTS: A literature search. CONCLUSIONS: The most important human enzymes activating AAI by simple nitroreduction in vitro are hepatic and renal cytosolic NAD(P)H:quinone oxidoreductase, hepatic microsomal cytochrome P450 (CYP) 1A2 and renal microsomal NADPH:CYP reductase as well as cyclooxygenase which is highly expressed in urothelial tissue. However, the contribution of most of these enzymes to the development of AAN and BEN diseases is still unclear. Hepatic CYP enzymes were found to detoxify AAI to AAIa in mice, and thereby protect the kidney from injury. CYP enzymes of the 1A subfamily seem to play a major role in this process in mouse liver. Likewise, among human CYP enzymes, CYP1A1 and 1A2 were found to be the most efficient enzymes participating in AAI oxidation to AAIa in vitro. Nevertheless, which CYPs are the most important in this process in both animal models and in humans have not been entirely resolved as yet. In addition, the relative contribution of enzymes found to activate AAI to species responsible for induction of urothelial cancer in humans remains still to be resolved.

Citace poskytuje Crossref.org

Bibliografie atd.

Lit.: 54

000      
00000naa 2200000 a 4500
001      
bmc10018501
003      
CZ-PrNML
005      
20111210182752.0
008      
100901s2009 xr e eng||
009      
AR
024    7_
$a 10.5507/bp.2009.001 $2 doi
035    __
$a (PubMed)19365519
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Stiborová, Marie, $d 1950-2020 $7 jo2005259907
245    14
$a The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers / $c Marie Stiborová, Eva Frei, Volker M. Arlt, Heinz H. Schmeiser
314    __
$a Department of Biochemistry, Faculty of Sciences, Charles University, Prague
504    __
$a Lit.: 54
520    9_
$a BACKGROUND: Ingestion of aristolochic acid (AA) is associated with the development of aristolochic acid nephropathy (AAN), which is characterized by chronic renal failure, tubulointerstitial fibrosis and urothelial cancer. AA may also cause another type of kidney fibrosis with malignant transformation of the urothelium, called Balkan Endemic Nephropathy (BEN). The compound predominantly responsible for the nephropathy and urothelial cancer of AA, is aristolochic acid I (AAI) which is a genotoxic mutagen after metabolic activation The activation pathway involves reduction of the nitro group to a cyclic N-acylnitrenium ion that can form covalent DNA adducts. These specific DNA adducts have been detected in experimental animals exposed to AAI, and in urothelial tissues from AAN patients. In rodent tumours induced by AAI, 7-(deoxyadenosin-N(6)-yl)aristolactam I was the most abundant DNA adduct formed and associated with activation of ras oncogenes through a characteristic transversion mutation. Such A:T-->T:A mutations have been identified in TP53 of urothelial tumour DNA of an AAN patient and in several patients suffering from BEN along with specific AA-DNA adducts. Understanding which enzymes are involved in AAI activation to species forming DNA adducts and/or detoxification to its O-demethylated metabolite aristolochic acid Ia (AAIa) is important in order to assess susceptibility to this carcinogen. METHODS AND RESULTS: A literature search. CONCLUSIONS: The most important human enzymes activating AAI by simple nitroreduction in vitro are hepatic and renal cytosolic NAD(P)H:quinone oxidoreductase, hepatic microsomal cytochrome P450 (CYP) 1A2 and renal microsomal NADPH:CYP reductase as well as cyclooxygenase which is highly expressed in urothelial tissue. However, the contribution of most of these enzymes to the development of AAN and BEN diseases is still unclear. Hepatic CYP enzymes were found to detoxify AAI to AAIa in mice, and thereby protect the kidney from injury. CYP enzymes of the 1A subfamily seem to play a major role in this process in mouse liver. Likewise, among human CYP enzymes, CYP1A1 and 1A2 were found to be the most efficient enzymes participating in AAI oxidation to AAIa in vitro. Nevertheless, which CYPs are the most important in this process in both animal models and in humans have not been entirely resolved as yet. In addition, the relative contribution of enzymes found to activate AAI to species responsible for induction of urothelial cancer in humans remains still to be resolved.
650    _2
$a financování organizované $7 D005381
650    _2
$a zvířata $7 D000818
650    _2
$a kyseliny aristolochové $x farmakokinetika $x toxicita $7 D034341
650    _2
$a biotransformace $7 D001711
650    _2
$a cytochrom P-450 CYP1A1 $x metabolismus $7 D019363
650    _2
$a cytochrom P-450 CYP1A2 $x metabolismus $7 D019388
650    _2
$a adukty DNA $x metabolismus $7 D018736
650    _2
$a aktivace enzymů $7 D004789
650    _2
$a lidé $7 D006801
650    _2
$a ledviny $x účinky léků $7 D007668
650    _2
$a nemoci ledvin $x chemicky indukované $7 D007674
650    _2
$a myši $7 D051379
650    _2
$a NADPH-cytochrom c-reduktasa $x metabolismus $7 D009251
650    _2
$a urologické nádory $x chemicky indukované $x metabolismus $7 D014571
655    _2
$a přehledy $7 D016454
700    1_
$a Frei, Eva. $7 _AN036392
700    1_
$a Arlt, Volker M. $7 xx0074763
700    1_
$a Schmeiser, Heinz H.
773    0_
$w MED00012606 $t Biomedical papers $g Roč. 153, č. 1 (2009), s. 5-11 $x 1213-8118
856    41
$u http://biomed.papers.upol.cz/pdfs/bio/2009/01/02.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 1502 $c 958 $y 7
990    __
$a 20100830113932 $b ABA008
991    __
$a 20100903123007 $b ABA008
999    __
$a ok $b bmc $g 767527 $s 631436
BAS    __
$a 3
BMC    __
$a 2009 $b 153 $c 1 $d 5-11 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $x MED00012606
LZP    __
$a 2010-22/mkme

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé